These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20938822)

  • 21. ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.
    Monteiro LL; Witjes JA; Agarwal PK; Anderson CB; Bivalacqua TJ; Bochner BH; Boormans JL; Chang SS; Domínguez-Escrig JL; McKiernan JM; Dinney C; Godoy G; Kulkarni GS; Mariappan P; O'Donnell MA; Rentsch CA; Shah JB; Solsona E; Svatek RS; van der Heijden AG; van Valenberg FJP; Kassouf W
    World J Urol; 2019 Jan; 37(1):51-60. PubMed ID: 30109483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
    Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
    Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
    Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
    Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Photodynamic therapy of superficial bladder cancer. An alternative to radical cystectomy?].
    Kriegmair M; Waidelich R; Baumgartner R; Lumper W; Ehsan A; Hofstetter A
    Urologe A; 1994 Jul; 33(4):276-80. PubMed ID: 7941172
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K; Chihara Y; Kondo H; Hirao Y
    Hinyokika Kiyo; 2006 Jun; 52(6):433-8. PubMed ID: 16848356
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radical cystectomy after bacillus Calmette-Guérin for high-risk Ta, T1, and carcinoma in situ: defining the risk of initial bladder preservation.
    Nieder AM; Simon MA; Kim SS; Manoharan M; Soloway MS
    Urology; 2006 Apr; 67(4):737-41. PubMed ID: 16618564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?
    Golabek T; Palou J; Rodríguez O; Gaya JM; Breda A; Villavicencio H
    World J Urol; 2017 Feb; 35(2):237-243. PubMed ID: 27277599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential Expression of PD-L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications.
    Wankowicz SAM; Werner L; Orsola A; Novak J; Bowden M; Choueiri TK; de Torres I; Morote J; Freeman GJ; Signoretti S; Bellmunt J
    J Urol; 2017 Oct; 198(4):817-823. PubMed ID: 28487100
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term follow-up of intravesical bacillus Calmette-Guérin treatment for superficial transitional-cell carcinoma of the bladder involving the prostatic urethra.
    Taylor JH; Davis J; Schellhammer P
    Clin Genitourin Cancer; 2007 Sep; 5(6):386-9. PubMed ID: 17956711
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.
    Eure GR; Cundiff MR; Schellhammer PF
    J Urol; 1992 Feb; 147(2):376-9. PubMed ID: 1732597
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intravesical bacillus Calmette-Guérin treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder.
    Baniel J; Grauss D; Engelstein D; Sella A
    Urology; 1998 Nov; 52(5):785-9. PubMed ID: 9801099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcome of conservative therapy for stage T1, grade 3 transitional cell carcinoma of the bladder.
    Hara I; Miyake H; Takechi Y; Eto H; Gotoh A; Fujisawa M; Okada H; Arakawa S; Kamidono S;
    Int J Urol; 2003 Jan; 10(1):19-24. PubMed ID: 12534921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy.
    Weiss C; Ott OJ; Wittlinger M; Krause SF; Fietkau R; Sauer R; Rödel C
    Strahlenther Onkol; 2008 Sep; 184(9):443-9. PubMed ID: 19016022
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [BCG versus photodynamic therapy (PDT) for nonmuscle invasive bladder cancer-a multicentre clinical phase III study].
    Jocham D; von Wietersheim J; Pflüger H; Steiner H; Doehn C; Büttner H; Böhle A; Kausch I
    Aktuelle Urol; 2009 Mar; 40(2):91-9. PubMed ID: 19214951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conservative treatment of high grade superficial bladder tumours.
    Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
    Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recurrence and progression of T1G3 transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guérin.
    Günlüsoy B; Değirmenci T; Arslan M; Nergiz N; Minareci S; Ayder AR
    Urol Int; 2005; 75(2):107-13. PubMed ID: 16123562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-inflammatory use may not negatively impact oncologic outcomes following intravesical BCG for high-grade non-muscle-invasive bladder cancer.
    Singla N; Haddad AQ; Passoni NM; Meissner M; Lotan Y
    World J Urol; 2017 Jan; 35(1):105-111. PubMed ID: 27194044
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
    Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
    Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.